Viral hepatitis: prognosis and problems


DOI: https://dx.doi.org/10.18565/epidem.2019.9.1.71-80

Mikhailov M.I., Kyuregyan K.K., Malinnikova E.Yu., Isaeva O.V., Karlsen A.A., Potemkin I.А., Kichatova V.S., Al-Sharabi Shukri A.S., Dogadov D.I., Korzaya L.I., Ignatieva M.E., Polyakov A.D.

1 Russian Medical Academy of Continuous Professional Education, Ministry of Health of Russia, Moscow, Russia; 2 I.I. Mechnikov Research Institute for Vaccines and Sera, Moscow, Russia; 3 Peoples’ Friendship University of Russia, Moscow, Russia; 4 Research Institute of Medical Primatology, Sochi, Russia; 5 Federal Service for Supervision of Consumer Rights Protection and Human Well-Being Directorate for the Republic of Sakha (Yakutia), Yakutsk, Russia; 6 Skolkovo Territorial Department of the Federal Service for Supervision of Consumer Rights Protection and Human Well-Being Directorate for the City of Moscow, Moscow, Russia
The problem of viral hepatitis is close to its solution. In 2016 WHO Global Health Sector Strategy for Viral Hepatitis for 2016–2021 has set the task for hepatitis control and elimination, and identified how to address it. The development of such a program has become possible due to the obtained fundamental knowledge about the nature of viral hepatitis, which allows to achieve this ambitious goal. Undoubtedly, the implementation of a program to control viral hepatitis in Russia, based on modern scientific knowledge and the realities of the epidemic process, will make it possible to solve the problem of controlling these diseases. However, new problems arise on this path. This publication addresses some of the current issues, in conjunction with own data. These problems may include: the possibility of the wide spread of hepatitis A virus among certain populations (hepatitis A outbreak in the USA in 2017–2018); the interspecies transmission of HEV from animals to humans; problems encountered in the implementation of the program for mass vaccination against HBV («Vaccine audit»); the history and characteristics of the circulation of the hepatitis D virus in various territories; distribution of circulating forms of the hepatitis C virus with drug resistance to direct-acting drugs (interferon-free therapy). New knowledge on the above mentioned issues are crucial for the successful implementation of the program for the control of viral hepatitis.
Keywords: prevention of viral hepatitis, elimination program, epidemic process, viral hepatitis, antiviral therapy, epidemiology
Read entire article

Literature

  1. Lemon S.M., Ott J.J., van Damme P., Shouval D. Type A viral hepatitis: A summary and update on the molecular virology, epidemiology, pathogenesis and prevention. J. Hepatol . 2017; 68 (1): 167–84.
  2. Foster M., Ramachandran S., Myatt K., Donovan D., Bohm S., Fiedler J. et al. Hepatitis A Virus Outbreaks Associated with Drug Use and Homelessness – California, Kentucky, Michigan and Utah, 2017. MMWR Morb Mortal Wkly Rep. 2018; 67(43): 1208–10. DOI:10.15585/mmwr.mm6743a3
  3. Parshli L., Mojer M.U. [New Diseases of the New World]. V Mire Nauki 2018; (7): 54–69. (In Russ.).
  4. Smith D.B., Simmonds Р., Jameel S. Consensus proposals for classification of the family Hepeviridae. J. Gen. Virol. 2014; 95: 2223–32.
  5. Woo P.C.Y., Lau S.K.P., Teng L.L., Cao K.Y., Wernery U., Schountz, T. et al. New Hepatitis E Virus Genotype in Bactrian Camels, Xinjiang, China, 2013. Emerg. Infect. Dis. 2016; 22(12): 2219–21.
  6. Teshale E.H., Hu D.J., Holmberg S.D. The two faces of hepatitis E virus. Clin. Infect. Dis. 2010; 51: 328–34.
  7. Mikhailov M.I., Malinnikova E.Yu., Kyuregyan К.К., Isaeva О.В. [The case of the importation of hepatitis E virus 4 genotype in Russia]. Zhurnal mikrobiologii, ehpidemiologii i immunobiologii 2016; (3): 64–9. (In Russ.).
  8. Mochammed А.М.Е., Potemkin I.А., Karlsen А.А., Isaeva О.В., Kyuregyan К.К., Kozlov V.G., Zhavoronok S.V., Mikhailov М.I. [The circulation of hepatitis E virus in rabbits in areas with different degrees of endemicity for hepatitis E]. Sovremennyye problemy nauki i obrazovaniya 2015; (2). https://science-education.ru/ru/article/ view?id=18395 (In Russ.).
  9. Kozhanova Т.V., Klushkina V.V., Gordeychuk I.V., Kyuregyan К.К., Mikhailov М.I. [Evaluation of the immunological efficacy of mass hepatitis B vaccination]. Trudy Instituta poliomielita i virusnyh ehncefalitov imeni M.P. Chumakova RAMN. Medicinskaya virusologiya 2014; 28(1): 16–25. (In Russ.).
  10. European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. J. Hepatol. 2018. pii. S0168-8278(18)31968-8. DOI: 10.1016/j.jhep.2018.03.026.
  11. Vermehren J., Susser S., Dietz.J., von Hahn T., Petersen J., Hinrichsen H. Retreatment of patients who failed DAA-combination therapies: real-world experience from a large hepatitis C resistance database. J. Hepatol. 2016; 64 (2): S188. DOI: https://doi.org/10.1016/S0168-8278(16)00128-8.
  12. Wyles D.L. Resistance to DAAs: When to Look and When It Matters. Curr. HIV/AIDS Rep. 2017; 14(6): 229–37. DOI: 10.1007/s11904-017-0369-5.
  13. Wyles D., Mangia A., Cheng W., Shafran S., Schwabe C., Ouyang W. Long-term persistence of HCV NS5A resistance associated substitutions after treatment with the HCV NS5A inhibitor, ledipasvir, without sofosbuvir. Antivir. Ther. 2017; 23(3):229-238. DOI: 10.3851/IMP3181.
  14. Abravanel F., Métivier S., Chauveau M., Péron J.-M., Izopet J. et al. Transmission of HCV NS5A Inhibitor–Resistant Variants Among HIV-Infected Men Who Have Sex With Men. Clin. Infect. Dis. 2016; 63(9): 1271–2.
  15. Nikitin I.G., Popovich L.D., Potapchik Е.G. [The economic burden of chronic hepatitis C in Russia]. Èpidemiologiâ i infekcionnye bolezni. Аktual’nye voprosy 2015; (6): 9–13. (In Russ.).
  16. Isaeva О.V., Kichatova V.S., Karlsen А.А., Solonin S.А., Dmitriev P.N., Kyuregyan К.К., Mikhailov М.I. [The long-term dynamics of the spread of the genotypes of the hepatitis C virus in the Moscow region]. Zhurnal mikrobiologii, ehpidemiologii i immunobiologii 2016; (4): 35–42. (In Russ.).
  17. Kichatova V.S., Karlsen А.А., Isaeva О.В., Solonin S.А., Malinnikova Е.Yu., Kyuregyan К.К., Mikhailov М.I. [Drug-resistant variants of HCV subtype 1b circulating in the Russian Federation: analysis of amino acid mutations in NS5a and core proteins]. Zhurnal infektologii 2018; 10(4): 30–6. DOI: 10.22625/2072-6732-2018-10-4-30-36. (In Russ.).
  18. Jacobson IM, Asante-Appiah E, Wong P, Black T, Howe AYM. Prevalence and impact of baseline NS5A resistance associated variants (RAVs) on the efficacy of elbasvir/grazoprevir (EBR/GZR) against GT1a infection. Hepatol. Baltim. Md. 2015; 62: 1393A–4A.
  19. Zeuzem S., Mizokami M., Pianko S., Mangia A, Han KH, Martin R. et al. NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome. J. Hepatol. 2017; 66(5): 910–8.
  20. Recommendations for Testing, Managing, and Treating Hepatitis C/HCV Guidance. http://hcvguidelines.org/.
  21. Mikhailov M.I, Yuchuck N.D. [The draft program for the control and elimination of viral hepatitis, as a public health problem]. Medicinskaya gazeta 2018; (11): 10–1. (In Russ.).
  22. Mikhailov M.I, Yuchuck N.D. Malinnikova Е.Yu., Kyuregyan К.К., Isaeva О.В., Znoyko О.О., Кlimova Е.А. [The draft program for the control and elimination of viral hepatitis, as a public health problem]. Infekcionnye bolezni: novosti, mneniya, obucheni. 2018; 7(2): 52–8. (In Russ.).


About the Autors

Prof. Mikhail I. Mikhailov, MD; Corresponding Member of the Russian Academy of Sciences; Scientific Director, Institute of Molecular and Personalized Medicine, Russian Medical Academy of Continuous Professional Education; Department Head, Laboratory of Viral Hepatitis I.I. Mechnikov Research Institute for Vaccines and Sera, Moscow, Russia; е-mail: michmich2@yandex.ru; ORCID: https://orcid.org/0000-0002-6636-6801
Karen K. Kyuregyan, BD, Professor of the Russian Academy of Sciences, Head, Department for the Study of Viral Hepatitis, Research Institute of Molecular and Personalized Medicine, Russian Medical Academy of Continuous Professional Education, Ministry of Health of Russia; Leading Researcher, Laboratory of Viral Hepatitis, I.I. Mechnikov Research Institute of Vaccines and Sera, Moscow, Russia; е-mail: karen-kyuregyan@yandex.ru; ORCID:http:// orcid.org/0000-0002-3599-117X
Elena Yu. Malinnikova, MD, Chief External Expert in Infectious Diseases, Ministry of Health of Russia; Head, Department of Virology, Russian Medical Academy for Continuous Professional Education, Ministry of Health of Russia; Leading Researcher, Laboratory of Viral Hepatitis, I.I. Mechnikov Research Institute of Vaccines and Sera, Moscow, Russia; е-mail: malinacgb@mail.ru; ORCID:https://orcid.org/ 0000-0002-5501-5707
Olga V. Isaeva, Cand. Biol. Sci., Leading Researcher, Department for the Study of Viral Hepatitis, Research Institute of Molecular and Personalized Medicine, Russian Medical Academy of Continuous Professional Education, Ministry of Health of Russia; Leading Researcher, Laboratory of Viral Hepatitis, I.I. Mechnikov Research Institute of Vaccines and Sera, Moscow, Russia; e-mail: isaeva.06@mail.ru;ORCID:https://orcid.org/0000-0002-2656-3667
Anastasiya A. Karlsen, Researcher, Department for the Study of Viral Hepatitis, Research Institute of Molecular and Personalized Medicine, Russian Medical Academy of Continuous Professional Education, Ministry of Health of Russia; Researcher, Laboratory of Viral Hepatitis, I.I. Mechnikov Research Institute of Vaccines and Sera, Moscow, Russia; e-mail: karlsen12@gmail.com; ORCID:http://orcid.org/ 0000-0002-6013-7768 
Ilya A. Potemkin, Researcher, Department for the Study of Viral Hepatitis, Research Institute of Molecular and Personalized Medicine, Russian Medical Academy of Continuous Professional Education, Ministry of Health of Russia; Researcher, Laboratory of Viral Hepatitis, I.I. Mechnikov Research Institute of Vaccines and Sera, Moscow, Russia; e-mail: axi0ma@mail.ru; ORCID: https://orcid.org/0000-0001-7559-4219
Vera S. Kichatova, Researcher, Department for the Study of Viral Hepatitis, Research Institute of Molecular and Personalized Medicine, Russian Medical Academy of Continuous Professional Education, Ministry of Health of Russia; Researcher, Laboratory of Viral Hepatitis, I.I. Mechnikov Research Institute of Vaccines and Sera, Moscow, Russia; e-mail: vera_kichatova@mail.ru; ORCID: http://orcid.org/ 0000-0002-7838-6965
Abdurakhman Said Al-Sharabi Shukri, Postgraduate Student, Department of Microbiology, Peoples’ Friendship University of Russia, Moscow, Russia; e-mail: biomedical1999@mail.ru
Dmitriy I. Dogadov, Researcher, Laboratory of Molecular Biology, Research Institute of Medical Primatology, Sochi, Russia; e-mail: dima_loko86@mail.ru; ORCID: https://orcid.org/ 0000- 0003-1596-0509
Lidiya I. Korzaya, Head, Laboratory of Molecular Biology, Research Institute of Medical Primatology, Sochi, Russia; e-mail: likorzaya@rambler.ru; ORCID: https://orcid.org/ 0000-0003-2259-5773
Margarita E. Ignatieva, Cand. Med. Sci., Head, Federal Service for Supervision of Consumer Rights Protection and Human Well-Being Directorate for the Republic of Sakha (Yakutia), Yakutsk, Russia; e-mail: akutia@14. rospotrebnadzor.ru
Andrey D. Polyakov, Cand. Med. Sci., Head, Skolkovo Territorial Department of the Federal Service for Supervision of Consumer Rights Protection and Human Well-Being Directorate for the City of Moscow, Moscow, Russia; e-mail: postoscol@mail.ru


Similar Articles

Back to Content

Бионика Медиа